BioSpace News Archive

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy.

Monteris Medical, the leader in MR-guided laser interstitial thermal therapy (LITT or laser ablation), announced today that Cigna, a global health services company and one of the largest commercial payors in the United States, has released a national coverage policy supporting the use of LITT for people with brain tumors and drug-resistant epilepsy.

Inceptor Bio (“Inceptor”), today announced an agreement with Arranta Bio (“Arranta”) for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio’s planned oncology clinical trials.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers (the “ Offers ”) to purchase for cash for a combined aggregate purchase price

Context Therapeutics Inc. and Wisconsin Oncology Network (WON), today announced the first patient has been dosed in the Phase 2 Trial

Werewolf Therapeutics, Inc. today announced that it will present preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021, in Washington, D.C., and virtually.

KemPharm, Inc. today announced that research involving AZSTARYS ® is being featured in a poster presentation during the 2021 Psych Congress being held both virtually and in-person in San Antonio, Texas

Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination

Sarepta Therapeutics, Inc. will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021.